DARPP-32, Jack of All Trades? Master of Which? by Marion Yger & Jean-Antoine Girault
BEHAVIORAL NEUROSCIENCE
REVIEW ARTICLE
published: 08 September 2011
doi: 10.3389/fnbeh.2011.00056
DARPP-32, jack of all trades. . . master of which?
MarionYger1,2,3 and Jean-Antoine Girault 1,2,3*
1 INSERM UMR-S 839, Paris, France
2 Université Pierre et Marie Curie, Paris, France
3 Institut du Fer à Moulin, Paris, France
Edited by:
Riccardo Brambilla, San Raffaele
Scientiﬁc Institute and University, Italy
Reviewed by:
Rosario Moratalla, Cajal Institute,
Consejo Superior de Investigaciones
Cientíﬁcas, Spain
Serge N. Schiffmann, Université Libre
de Bruxelles, Belgium
*Correspondence:
Jean-Antoine Girault , INSERM
UMR-S 839, Institut du Fer à Moulin,
Université Pierre et Marie Curie, 17
rue du Fer à Moulin, 75005 Paris,
France.
e-mail: jean-antoine.girault@inserm.fr
DARPP-32 (PPP1R1B) was discovered as a substrate of cAMP-dependent protein kinase
(PKA) enriched in dopamine-innervated brain areas. It is one of three related, PKA-regulated
inhibitors of protein phosphatase-1 (PP1). These inhibitors seem to have appeared in
early vertebrate ancestors, possibly Gnathostomes. DARPP-32 has additional important
biochemical properties including inhibition of PKA when phosphorylated by Cdk5 and reg-
ulation by casein kinases 1 and 2. It is highly enriched in speciﬁc neuronal populations,
especially striatal medium-size spiny neurons. As PP1 inhibitor DARPP-32 ampliﬁes and/or
mediates many actions of PKA at the plasma membrane and in the cytoplasm, with a
broad spectrum of potential targets and functions. DARPP-32 also undergoes a continuous
and tightly regulated cytonuclear shuttling. This trafﬁcking is controlled by phosphoryla-
tion of Ser-97, which is necessary for nuclear export. When phosphorylated on Thr-34 and
dephosphorylated on Ser-97, DARPP-32 can inhibit PP1 in the nucleus and modulate signal-
ing pathways involved in the regulation of chromatin response. Recent work with multiple
transgenic and knockout mutant mice has allowed the dissection of DARPP-32 function in
striato-nigral and striato-pallidal neurons. It is implicated in the action of therapeutic and
abused psychoactive drugs, in prefrontal cortex function, and in sexual behavior. However,
the contribution of DARPP-32 in human behavior remains poorly understood. Post-mortem
studies in humans suggest possible alterations of DARPP-32 levels in schizophrenia and
bipolar disorder. Genetic studies have revealed a polymorphism with possible association
with psychological and psychopathological traits. In addition, a short isoform of DARPP-32,
t-DARPP, plays a role in cancer, indicating additional signaling properties.Thus, DARPP-32 is
a non-essential but tightly regulated signaling hubmolecule whichmay improve the general
performance of the neuronal circuits in which it is expressed.
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What we know today about signal transduction derives from early
studies of the glycogen metabolism. Sutherland (1972) identi-
ﬁed cAMP as the intracellular second messenger which mediates
the action of glucagon and epinephrine on glycogen degradation
through activation of glycogen phosphorylase. Edwin G. Krebs
and Edmond H. Fischer identiﬁed the role of the ﬁrst protein
kinase (PKA), phosphorylase kinase, in activating phosphorylase
(see Fischer, 1997). In 1968, Krebs and Walsh discovered that
cAMP action was mediated by activation of cAMP-dependent
PKA, which activated phosphorylase kinase (Walsh et al., 1968).
Paul Greengard and his collaborators then showed that similar
cascades of biochemical reactions were critical in the action of
neurotransmitters in the nervous system (Nestler and Greengard,
1983; Greengard, 2001). They identiﬁed the ﬁrst dopamine (DA)
receptor by its positive coupling to adenylyl-cyclase (Kebabian
et al., 1972) and downstream protein phosphorylation (Krueger
et al., 1975). To better characterize the mode of action of neu-
rotransmitters in various brain regions, Walaas et al. (1983b)
undertook a systematic regional study of proteins phosphorylated
by second messengers-activated protein kinases. Some of these
substrates, or “third messengers” were evenly distributed whereas
others were highly enriched in speciﬁc brain regions. For example,
Walaas observed the enrichment of a 32-kDa soluble PKA sub-
strate in striatal slices extracts. The phosphorylation of this protein
highly expressed in DA-innervated brain regions, was regulated
by DA and cAMP and it was termed DARPP-32 (dopamine and
cAMP-regulatedphospho-proteinMr32,000;Walaas et al., 1983a).
DARPP-32 had properties similar to those of protein phosphatase-
1 (PP1) inhibitor-1 and was shown to be a potent inhibitor of PP1
when phosphorylated by PKA (Hemmings et al., 1984a). Hence,
DARPP-32 is also known as phospho-protein phosphatase-1 reg-
ulatory subunit 1B (PPP1R1B), although its properties are not
restricted to PP1 inhibition (see below). DARPP-32 is expressed
only in some speciﬁc neuronal populations in the brain and at
low levels in a few non-neuronal cell types in the brain (e.g., tany-
cytes, choroid plexus) and other organs (e.g., adrenal medulla,
parathyroid cells, kidney thick ascending limbof the loop of Henle;
Ouimet et al., 1984;Hemmings andGreengard,1986;Meister et al.,
1989). Not all of these cells express adenylyl-cyclase-coupled DA
receptors (D1R and D5R) and DARPP-32 phosphorylation on
Frontiers in Behavioral Neuroscience www.frontiersin.org September 2011 | Volume 5 | Article 56 | 1
Yger and Girault DARPP-32
the cAMP site (Thr-34; Hemmings et al., 1984c) can be regu-
lated by many other extracellular messengers (see Greengard et al.,
1999; Girault and Greengard, 2004; Svenningsson et al., 2004 for
reviews). Thus, DARPP-32 has been implicated in many physio-
logical and pathological responses involving the basal ganglia, and
other brain regions and peripheral organs. Here we review the
major molecular properties of DARPP-32 and we focus on recent
ﬁndings on its possible roles based on studies in animal models as
well as on correlations in humans. We also try to put its molec-
ular properties in perspective with the known function of striatal
neurons.
MOLECULAR PROPERTIES OF DARPP-32
DARPP-32 IS A PHOSPHORYLATION-DEPENDENT INHIBITOR OF PP1
REGULATED BY CYCLIC NUCLEOTIDES-DEPENDENT PROTEIN KINASES
The biochemical properties of DARPP-32 have raised a great inter-
est because of the surprising complexity of the effects of its phos-
phorylation at various sites. The most extensively studied is the
phosphorylation of Thr-34 which turns DARPP-32 into a potent
inhibitor of PP1 (Hemmings et al., 1984a). Thr-34 in DARPP-32,
like Thr-35 in inhibitor-1 are excellent substrates for both PKA
and cGMP-dependent protein kinases (Hemmings et al., 1984b).
They are dephosphorylated by the calcium/calmodulin activated
phosphatase 2B (PP2B, also known as calcineurin or PPP3) and by
the catalytic subunit of protein phosphatase 2A (PP2A or PPP2)
in vitro (Hemmings et al., 1984a; King et al., 1984) and in striatal
neurons (Halpain et al., 1990; Nishi et al., 1999).
Protein phosphatase-1 is a major, highly conserved Ser/Thr
phosphatase, involved in virtually all cell functions including
cell cycle, muscle contraction, carbohydrate metabolism, neu-
ronal signaling, and transcription (see Bollen et al., 2010 for
a recent review). The activity of PP1 catalytic subunit (PP1c)
is controlled by numerous interacting proteins acting as target-
ing subunits, substrates, and/or inhibitors (Bollen et al., 2010).
Most of these proteins contain a degenerate docking sequence
K/R-K/R-V/I-x-F/W necessary for binding PP1c, without chang-
ing its conformation (Egloff et al., 1997; Bollen et al., 2010). It
has been shown by X-ray crystallography that this motif inter-
acts with a hydrophobic channel located on the opposite side
of PP1c active site (Egloff et al., 1997). However, binding to
this motif does not inhibit PP1, implying that other domains
of inhibitors must interact with the phosphatase to regulate its
activity. The docking motif is also found in targeting subunits
and can compartmentalize PP1, bringing it into proximity to its
substrates, including GADD34, the myosin phosphatase target-
ing subunit MYPT1, PNUTS, and spinophilin (see Bollen et al.,
2010 for references). Among PP1 inhibitors the PPP1R1 family
includes inhibitor-1 (PPP1R1A; Aitken et al., 1982), DARPP-32
(PPPR1B), and the much less well characterized inhibitor of
protein phosphatase 5 (IPP-5 or PPP1R1C; Wang et al., 2008),
which share a conserved region of about 50-residues (Figure 1).
Phylogenetic studies using immunoblotting detected DARPP-
32-like proteins in dopaminoceptive brain regions from repre-
sentative members of the amniote vertebrate classes (birds and
reptiles), while none was identiﬁed in dopaminoceptive brain
regions from representative members of the anamniote vertebrate
classes (bony ﬁshes and amphibians; Hemmings and Greengard,
1986). With the same approach inhibitor-1-like immunoreac-
tivity was detected in anamniote and amphibian representatives
(Hemmings et al., 1992). However such studies are limited by
the lack of conservation of epitopes. Indeed sequence compar-
isons show that all three PPP1R1 family members are actually
found in Osteichthyes including bony ﬁsh, amphibians lizards,
birds, and mammals (Figure 2). We also detected short pre-
dicted sequences similar to PPP1R1B and PPP1R1C in Elephant
shark genome (http://esharkgenome.imcb.a-star.edu.sg/), a carti-
laginous ﬁsh, although the sequence coverage is not yet sufﬁcient
to determine precisely the conservation of these genes in Chon-
drichthyes. In contrast no homologous sequence was found in
Petromyzontoids (jawless ﬁsh, e.g., lamprey) and invertebrates.
These data, albeit still incomplete, suggest that the PP1R1 fam-
ily arose in early vertebrate ancestors, possibly in Gnathostomes,
which encompass both bony and cartilaginous ﬁsh.
pT34-DARPP-32 inhibits PP1c with mixed competitive and
uncompetitive kinetics (Hemmings et al., 1984a, 1990). Residues
8-38, which are highly conserved between the three members of
the PPP1R1 family are necessary and sufﬁcient for PP1 inhibition
(Hemmings et al., 1990). The N-terminal region of DARPP-32
encompasses a K7KIQF motif that corresponds to the canonical
PP1 interacting motif. This motif is essential for PP1 inhibition
(Kwon et al., 1997) and probably accounts in part for the abil-
ity of dephospho-DARPP-32 or Thr-34-Ala DARPP-32 to inhibit
FIGURE 1 | Multiple sequence alignment of human PPP1R1 family members. Human amino acid sequences of PPP1R1C (IPP-5,
gi|17389867|gb|AAH17943.1|), PPP1R1A (I-1, gi|48146123|emb|CAG33284.1|), and PPP1R1B (DARPP-32, gi|119580986|gb|EAW60582.1|) were obtained from
NCBI data base and aligned by Clustalview. Identical residues are shaded black and similar ones gray. The known phosphorylation sites are in red and the PP1
binding motif in green.
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FIGURE 2 | Phylogeny of PPP1R1 family.The evolutionary history was
inferred using the Neighbor-Joining method (Saitou and Nei, 1987). The
optimal tree with the sum of branch lengths=1.395 is shown. The tree is
drawn to scale, with branch lengths in the same units as the evolutionary
distances used to infer the phylogenetic tree (number of amino acid
differences per site). The evolutionary distances were computed using the
p-distance method (Nei and Kumar, 2000). Positions containing gaps and
missing data were eliminated. There were a total of 42 positions in the ﬁnal
dataset. Evolutionary analyses were conducted in MEGA5 (Tamura et al.,
2011). The 17-amino acid sequences analyzed were: PPP1R1A
gi|326935910| ref|XP_003214007.1| (Meleagris gallopavo, wild turkey),
gi|227337247|gb|ACP21475.1| (Carassius auratus, gold ﬁsh), gi|48146123|
emb|CAG33284.1| (Homo sapiens), gi|10946734| ref|NP_067366.1| (Mus
musculus house mouse), gi|62859473| ref|NP_001015900.1| (Xenopus
tropicalis, Western clawed frog); PPP1R1B: gi|119580986| gb|EAW60582.1|
(Homo sapiens), gi|21536256| ref|NP_659077.1| (M. musculus),
gi|156717604| ref|NP_001096342.1| (X. tropicalis), gi|327275684|
ref|XP_003222603.1| (Anolis carolinensis, Carolina anole, a lizard),
gi|326936204| ref|XP_003214147.1| (M. gallopavo), gi|213515022|
ref|NP_001133145.1| (Salmo salar, Atlantic salmon); PPP1R1C: gi|50540138|
ref|NP_001002538.1| (Danio rerio, zebraﬁsh), gi|327278420|
ref|XP_003223960.1| (A. carolinensis), gi|122889495| emb|CAM14502.1|
(M. musculus), gi|17389867| gb|AAH17943.1| (Homo sapiens),
gi|284413766| ref|NP_001165134.1| (X. tropicalis), gi|326922651|
ref|XP_003207562.1| (M. gallopavo).
PP1 with an IC50 in the micromolar range (Desdouits et al.,
1995a). Phosphorylation of Thr-34 provides a high afﬁnity inhi-
bition (nanomolar IC50), whereas the replacement of pThr by
pSer or Glu is much less efﬁcient (Hemmings et al., 1990; Des-
douits et al., 1998). The two Pro residues ﬂanking Thr-34 are also
important, as well as the distance between the KKIQF and PpTP
motifs (Huang et al., 1999). Thus, it is highly likely that inhibi-
tion by DARPP-32 results from a bidentate interaction with PP1c,
involving regions located on twoopposite sides of the phosphatase:
binding of the KKIQF motif to the superﬁcial hydrophobic chan-
nel and interaction of PpTP with the active site in a conformation
that does not allow dephosphorylation (Hemmings et al., 1990;
Kwon et al., 1997; Huang et al., 1999). Like several other PP1
inhibitors, DARPP-32 appears to be an intrinsically disordered
protein with little identiﬁable secondary structure (Neyroz et al.,
1993; Dancheck et al., 2008;Marsh et al., 2010), a particularity that
may be well suited for a ﬂexible interaction with two diametrically
opposed binding sites on PP1c.
DARPP-32 IS PHOSPHORYLATED BY SEVERAL KINASES WITH
MULTIPLE CONSEQUENCES
DARPP-32 is regulated by multiple phosphorylation sites
(Figure 3). Cdk5, a cyclin-dependent kinase family member acti-
vated in neurons by its co-factor p35, phosphorylates DARPP-32
onThr-75 (Bibb et al., 1999).When it is phosphorylatedonThr-75,
DARPP-32 inhibits PKA in vitro with a purely competitive kinet-
ics and a Ki of 2.7μM using cAMP-regulated phospho-protein
of 21 kDa (ARPP-21, also known as regulator of calmodulin sig-
naling, RCS) as a substrate (Bibb et al., 1999). DARPP-32 is also
phosphorylated on Ser-45 and Ser-97 (Ser-102 in rat sequence) by
casein kinase 2 (CK2; Girault et al., 1989a). Phosphorylation by
CK2 increases the action of PKA on Thr-34, but not that of cGMP-
dependent protein kinase on that site (Girault et al., 1989a). It is
not known whether this effect results from phosphorylation of
Ser-45 or Ser-97, or both, nor what the physiological relevance
of this facilitation is in vivo. An important effect of phosphory-
lation of Ser-97 is to enhance the nuclear export of DARPP-32
(Stipanovich et al., 2008 see below). DARPP-32 is also phos-
phorylated on Ser-130 (Ser-137 in rat) by casein kinase 1 (CK1;
Desdouits et al., 1995b), and this phosphorylation decreases the
dephosphorylation of Thr-34 by calcineurin, in vitro and in vivo
(Desdouits et al., 1995c). The molecular mechanisms underlying
the modulatory effects of CK1 and CK2 are not elucidated. Since
DARPP-32 appears to be intrinsically unstructured, it is unlikely
that the facilitation of PKA action and inhibition of calcineurin
action result from allosteric effects stricto sensu. Instead they may
be related to changes in interactions with the relevant enzymes
throughdistant binding sites, and/or to intramolecular folding and
interactions within the DARPP-32 molecule, as suggested by NMR
studies (Dancheck et al., 2008). In addition to the sites described
above, Ser-192 has also been found to be phosphorylated in mouse
brain (Jin et al., 2005), but this site is not conserved in several
mammalian species and its functional role, if any, is not known.
The dephosphorylation of DARPP-32 by various protein phos-
phatases has been studied in vitro and in intact cells. Calcineurin
dephosphorylates Thr-34 (King et al., 1984; Halpain et al., 1990;
Nishi et al., 1999), PP2A dephosphorylates Thr-34, Ser-45, Thr-75,
and Ser-97 (Girault et al., 1989a;Hemmings et al., 1990; Bibb et al.,
1999; Nishi et al., 1999). In striatal neurons dephosphorylation of
Ser-130 is mostly accounted for by PP2C (Desdouits et al., 1998).
PP2A is an heterotrimeric enzyme comprising a catalytic subunit
C, a scaffolding subunit A, and a variable regulatory subunit B
(Janssens et al., 2008). The B56δ subunit (also known as PR61δ,
B′δ or PPP2R5D) is enriched in the striatum andmediates dephos-
phorylation of Thr-75 and Ser-97 in response to PKA activation
(Nishi et al., 2000a; Ahn et al., 2007a; Stipanovich et al., 2008). The
PR72/B′ (PPP2R3A) subunit, which contains two Ca2+ binding
sites, accounts for the Ca2+-induced dephosphorylation of Thr-
75 (Nishi et al., 2002; Ahn et al., 2007b). Thus, the activity of PP2A
appears to be regulated by multiple pathways which depend on the
nature of the regulatory and inhibitory subunits that are expressed
in the cell. An additional layer of regulation potentially important
in striatal neurons has been revealed recently by the discovery that
proteins related to ARPP-16, which is enriched in striatal neurons
(Girault et al., 1990), are potent inhibitors of PP2A (Gharbi-
Ayachi et al., 2010; Mochida et al., 2010). This effect requires
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FIGURE 3 | Multisite phosphorylation of DARPP-32. Schematic representation of mouse DARPP-32 with the residues that have been found phosphorylated
in vivo (Thr-34, Ser-45, Thr-75, Ser-97, Ser-130, Ser-192). The identiﬁed kinases are indicated above green arrows (phosphorylation), and protein phosphatases
beside the red arrows (dephosphorylation). The role of the phosphorylation is given for each residue. See the text for discussion and references. P, phosphate.
phosphorylation by Greatwall, a PKA that has several orthologous
isoforms in mammals (microtubule associated serine/threonine
kinase like, MASTL1-4). The role of this pathway on PP2A regu-
lation and indirectly on PP1 in the striatum remains to be investi-
gated. Another interesting regulation of PP2A in D2R-expressing
neurons is related to its recruitment by β-arrestin following recep-
tor internalization (Beaulieu et al., 2005), but its role in the
regulation of DARPP-32 has not been investigated.
The phosphorylation sites of DARPP-32 and their effects on
kinases andphosphatases, including thosewhich act onDARPP-32
itself, weave a complex network of positive and negative feedback
and feedforward loops. Several computational models have been
built to better understand the complex regulation of these four
sites and predict the output of the pathway depending on the lev-
els of DA and glutamate, or of cAMP and Ca2+ (Fernandez et al.,
2006; Lindskog et al., 2006; Barbano et al., 2007; Le Novère et al.,
2008; Nakano et al., 2010; Qi et al., 2010). Kinetic models using
differential equations showed that DARPP-32 is not only a robust
signal integrator, but that its response also depends on the delay
between cAMP and calcium signals (Fernandez et al., 2006) and
that Thr-34 phosphorylation is potentiated by the coincidence of
the two stimuli (Lindskog et al., 2006). DARPP-32 appears capable
to translate the various states of glutamate and DA input into dis-
tinct steady states and/or dynamic responses (Qi et al., 2010) and
the positive feedback loop consisting of PKA, PP2A, and Thr-75
phosphorylation may serve as a major switch for inducing LTD
and LTP (Nakano et al., 2010). Interestingly this loop displayed
robust bi-stable responses but was disrupted by high basal levels
of DA. Other authors have used large-scale numerical simulation
and sophisticated mathematical approach to model the DARPP-
32 network and evaluate its resistance to perturbations (Barbano
et al., 2007)1. They showed that the global network topology sta-
bilized the net state of DARPP-32 phosphorylation in response to
1The approach of Barbano et al. (2007) does not require knowledge of initial con-
centrations or kinetic parameters, but uses random arbitrary values to calculate
steady state equilibrium concentrations of all chemical reagents for various ratios
of DA and glutamate inputs. Simulations are repeated in the presence of superim-
posed noise. The results of each simulation represent coordinates of a single point
variations of the input levels of DA and glutamate, despite signif-
icant perturbation to the concentrations and levels of activity of
a number of intermediate chemical species (Barbano et al., 2007).
Interestingly the whole network used in the model was necessary
to provide this resistance to perturbation, providing a possible a
posteriori justiﬁcation for its apparent complexity.Altogether these
modeling studies indicate that DARPP-32 is a very robust sensor
of glutamate and DA inputs with intrinsic abilities to stably ori-
ent the cell responses in the presence of noise. This may suggest
that a major function of DARPP-32 is to increase the reliability
of signal processing in medium-size spiny neurons (MSNs) of the
striatum.
DARPP-32 IS A MESSENGER BETWEEN THE CYTOPLASM AND THE
NUCLEUS
Since PP1 dephosphorylates many targets of PKA in neurons,
DARPP-32 has been implicated in the regulation by DA of several
ion channels in striatal neurons, including the AMPA and NMDA
glutamate receptors (NMDAR) and voltage-gated Na+ and Ca2+
channels (see Svenningsson et al., 2004 for a review). A recent
study has revealed an additional level of complexity concerning
the signaling properties of DARPP-32, by showing its regulated
cytonuclear trafﬁcking (Stipanovich et al., 2008). Although the
presence of DARPP-32 immunoreactivity in the nucleus of some
striatal MSNs, but not in others, was clearly established by elec-
tron microscopy early in the study of this protein (Ouimet and
Greengard, 1990), the signiﬁcance of this observation was unclear.
Studies in neurons in culture with the inhibitor of nuclear export
leptomycin B revealed that DARPP-32 undergoes a continuous
shuttling between the cytoplasm and the nucleus (Stipanovich
et al., 2008). Its import is facilitated by several sequences in the
N-terminal region, while the nuclear export requires a speciﬁc
sequence with nuclear export signal features and the phospho-
rylation of Ser-97. Accordingly, the protein is mostly found in
in a space with as many dimensions as reagents in the network. The authors then
use non-linear dimensionality reduction methods, such as locally linear embedding,
to compare the resulting curves in the absence or presence of various amounts of
noise and determine the resistance of the network to perturbations.
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the nucleus in knock-in mice bearing a Ser-97-Ala DARPP-32
mutation (Stipanovich et al., 2008). Treatment of mice with addic-
tive drugs or operant learning increases the proportion of nuclear
DARPP-32, a response mimicked in vitro by cAMP analogs (Sti-
panovich et al., 2008). Dephosphorylation of Ser-97 by PP2A is an
important factor in these regulations. It can be triggered by acti-
vation of the isoform containing the B56δ subunit (Stipanovich
et al., 2008), as well as by other signaling pathways (Matamales
and Girault, unpublished observations).
PP1 is present in the nucleus of cells where it plays important
roles (Moorhead et al., 2007) with PP1α being the predomi-
nant nuclear isoform in MSNs (Ouimet et al., 1995). Following
activation of D1R, pT34-DARPP-32 is enriched in the nucleus
and this facilitates the phosphorylation of histone H3 on Ser-
10 (Stipanovich et al., 2008), a site dephosphorylated by PP1
(Hsu et al., 2000). Phosphorylation of histone H3 Ser-10 dur-
ing the interphase promotes detachment of speciﬁc regions from
the heterochromatic scaffold to allow decondensation and gene
expression, in combination with other histone post-translational
modiﬁcations (Johansen and Johansen, 2006). Since PP1 hasmany
substrates in the nucleus (Moorhead et al., 2007), it is likely that
the consequences of the accumulation of pT34-DARPP-32 has
multiple consequences on chromatin and other nuclear targets.
For example, a recent report shows that DARPP-32 interacts with
tra2-beta1, a factor involved in the regulation of alternative splic-
ing (Benderska et al., 2010). This latter observation suggests a
possible role of DARPP-32 in the regulation of alternative splicing
an important but little understood process in neurons.
DISTINCT ROLES OF DARPP-32 IN STRIATO-NIGRAL AND
STRIATO-PALLIDAL MSNs
DARPP-32 IS HIGHLY CONCENTRATED IN ALL STRIATAL MEDIUM-SIZE
SPINY NEURONS
DARPP-32 concentrations are the highest (20–50μM) in striatal
MSNs (Hemmings and Greengard, 1986). The striatum, which
consists of a dorsal region, the caudate–putamen (CP), and a
ventral region, the nucleus accumbens (NAc), is the major entry
station of the basal ganglia. It is comprised of MSNs which are
GABAergic efferent neurons making up to 95% of striatal neu-
rons in rodents, and of several types of interneurons, including
large cholinergic and diverse medium-size GABAergic neurons
(Tepper and Bolam, 2004). MSNs receive massive glutamatergic
inputs from virtually all cortical areas and the thalamus, and a
dense dopaminergic innervation from the substantia nigra pars
compacta (dorsolateral CP) and the ventral tegmental area (VTA;
dorsomedial CP and NAc). MSNs belong to two different popu-
lations which project to the substantia nigra pars reticulata either
directly or indirectly through relays in the lateral globus pallidus
and subthalamic nucleus. D1 DA receptors (D1R) are preferen-
tially expressed in striato-nigral MSNs of the direct pathway and
D2R in striato-pallidalMSNs of the indirect pathway (Gerfen et al.,
1990; see also Valjent et al., 2009; Bertran-Gonzalez et al., 2010 for
recent reviews). Thus, the circuits in which MSNs play an essen-
tial role integrate signals coming from many brain regions with
modulatory information coded by DA neurons in relation with
reward prediction errors (Schultz, 2002) and motivational salience
(Bromberg-Martin et al., 2010). The basal ganglia loops control
many aspects of movements and motivation and their function
has been proposed to be related to action selection (Mink, 1996;
Redgrave et al., 1999). This is dependent on the balance between
the two trans-striatal circuits, involving the direct and indirect
pathways. Their disequilibrium accounts for the consequences of
the striatal alterations in several pathological conditions, including
Parkinson’s disease due to the lack of DA following degeneration
of DA neurons and addiction, related to the common capacity of
abused substances to increase extracellular DA (Di Chiara, 1999).
DARPP-32 has been implicated in various aspects of striatal func-
tions and dysfunctions, with distinct consequences in the direct
and indirect pathways.
DARPP-32 IS DIFFERENTIALLY REGULATED IN THE TWO POPULATIONS
OF MSNs
DARPP-32 is present in virtually all MSNs (Ouimet et al., 1998)
and equally expressed in the D1R-expressing striato-nigral neu-
rons (indirect pathway) and D2R-expressing striato-pallidal neu-
rons (direct pathway; Bertran-Gonzalez et al., 2008). A number of
drugs have been reported to alter DARPP-32 phosphorylation at
its various sites in striatal slices in vitro and in the striatum in vivo
(see Svenningsson et al., 2004). Some of these studies apparently
had contradictory results, showing for example that agents that
either increase DA transmission, such as cocaine, or block DA
transmission, such as antipsychotics, both increased DARPP-32
phosphorylation on Thr-34 (Svenningsson et al., 2000). The fact
that increased phosphorylation was due to stimulation of D1R
or blockade of D2R, and that the latter effect was prevented by
A2a antagonists2 suggested that this effect was due to the differ-
ent regulation of DARPP-32 in D1R- and D2R-expressing MSNs
(Svenningsson et al., 2000). This hypothesis was formally proven
by the use of bacterial artiﬁcial chromosome (BAC) transgenic
mice expressing DARPP-32 fused to two different peptide tags,
under the control of drd1a (D1R) or drd2 (D2R) promoters,
respectively (Bateup et al., 2008). Selective immunoprecipitation
with antibodies against one peptide tag or the other showed that,
as expected, cocaine-induced phosphorylation of DARPP-32 at
Thr-34 in D1Rneurons and decreased it in D2R- neurons, while
it decreased Thr-75 phosphorylation in D1R- and increased it in
D2R-neurons (Bateup et al., 2008). Haloperidol increased selec-
tively Thr-34 phosphorylation inD2R-neurons. Surprisingly how-
ever, the in vivo effects of selective D1R or D2R agonists appeared
more complex: SKF81297, a D1R agonist, increased Thr-34 phos-
phorylation in both neuronal populations, whereas quinpirole,
a D2R agonist, decreased Thr-34 and increased Thr-75 phos-
phorylation in both neuronal populations (Bateup et al., 2008).
The effects of the D2 agonist on D1R-expressing neurons were
easily explained by the decreased release of endogenous DA fol-
lowing the stimulation of D2 autoreceptors on DA terminals. In
contrast, the mechanisms of the effects of the D1 agonist on D2R-
expressing neurons were not completely clear and may reﬂect the
recruitment of extrastriatal D1R. It is interesting to note that in
the study of Bateup et al. (2008), as in others (Bertran-Gonzalez
2A2a receptors are selectively expressed in striato-pallidal neurons in which they
stimulate adenylyl-cyclase, thereby opposing the effects of D2R which inhibit
adenylyl-cyclase.
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et al., 2008), the in vivo actions of cocaine that non-selectively
increases extracellular DA and other monoamines, appeared more
speciﬁc on striato-nigral D1R-expressing neurons than those of
selective D1 agonists. This unexpected observation suggests that
the coordinated stimulation of D1R and D2R by endogenous DA
is particularly well suited to exert contrasted and opposing effects
on the two populations of MSNs, probably reﬂecting a fundamen-
tal intrinsic property of the functional organization of the basal
ganglia.
THE FUNCTIONAL CONSEQUENCES OF THE ABSENCE OF DARPP-32 ARE
DISTINCT IN THE TWO POPULATIONS OF MSNs
To investigate the role of DARPP-32 in the two populations of
striatal MSNs from a behavioral standpoint, Bateup et al. (2010)
have used conditional knockout in D1R or in D2R-expressing
MSNs. The absence of DARPP-32 inD1RMSNs reduced basal and
cocaine-induced locomotor activity whereas the loss of DARPP-
32 in D2R MSNs had the opposite effect. The opposite effects on
motor behavior in the two populations of striatal neurons may
explain why the complete knockout had relatively little effect on
spontaneous motricity (Fienberg et al., 1998; Hiroi et al., 1999).
In a rodent model of Parkinson’s disease, in which the striatal
dopaminergic input is destroyed by 6-OH-DA, chronic admin-
istration of l-DOPA-induced phosphorylation of DARPP-32 at
Thr-34 (Santini et al., 2007). Chronic l-DOPA treatment of DA-
lesioned rodents often triggers abnormal involuntary movements
(AIMs), which are thought to model l-DOPA-induced dyskinesia
observed in patients (Cenci, 2007). Interestingly, phosphoryla-
tion of both DARPP-32 and extracellular signal regulated kinase
(ERK) was correlated with the occurrence of AIMs (Santini et al.,
2007). D1R is critical for the development of l-DOPA-induced
AIMS (Darmopil et al., 2009) and l-DOPA selectively induced
ERK phosphorylation in D1R-expressing neurons (Santini et al.,
2009).AIMs inductionwas diminishedwhen l-DOPAwas admin-
istered with a drug preventing ERK activation or in DARPP-32
knockout mice (Santini et al., 2007). Although this suggests a
causal relationship between DARPP-32 phosphorylation and ERK
activation (Santini et al., 2007), other authors found that ERK
phosphorylation was not blocked in the dorsal striatum in similar
conditions (Gerfen et al., 2008). The reason for this discrepancy is
not known. However, the prominent role of DARPP-32 in striato-
nigral neurons in the generation of l-DOPA-induced AIMs was
shown by their absence in mice in which DARPP-32 was deleted
in D1R-expressing neurons, but not in those in which the dele-
tion was induced in D2R-expressing neurons (Bateup et al., 2010).
This result is in agreement with those obtained in D1R knockout
mice (Darmopil et al., 2009). In conclusion, the ERK pathway and
DARPP-32 in striato-nigral neurons appear to be both involved in
the appearance of AIMs but the precise relationship between the
two is not fully understood.
MULTIPLE ROLES OF DARPP-32 IN REWARD AND THE
ACTION OF DRUGS OF ABUSE
It is well established that the mesencephalic DA neurons play
an important role in reward-related behaviors (see for example
Schultz, 2002 for a review). Little is known about the involve-
ment of DARPP-32 in physiological reward-controlled learning.
Although DARPP-32 seems not to be crucial for reward learning,
the reversal learning after a conditioning operant task by nose pok-
ing was impaired in DARPP-32 KO mice (Heyser et al., 2000). In
knock-in mice with a Ser-97-Ala point mutation, operant learning
was normal but themotivation for food rewardwas decreased (Sti-
panovich et al., 2008). Drugs of abuse share the ability to increase
DA transmission (Wise, 1987; Di Chiara, 1999), and the role of
DARPP-32 in mediating their actions has been studied for mol-
ecules as different as cocaine, amphetamine, nicotine, caffeine,
ethanol, and opiates (see Nairn et al., 2004 for a review). One
of the signaling pathways which appear to be important for the
long-term behavioral effects of drugs of abuse is the ERK cascade
which is activated in response to all tested drugs of abuse (Valjent
et al., 2000, 2004; Ibba et al., 2009). ERK phosphorylation requires
activation of both D1R and NMDAR, occurs in D1R-expressing
neurons, and is prevented in DARPP-32 knockout or Thr-34-Ala
knock-in mice (Valjent et al., 2005). Thus, although DARPP-32 is
not necessary for the potentiation of NMDAR by D1R that leads to
ERK phosphorylation in neurons in culture (Pascoli et al., 2011), it
appears to be necessary for the activation of ERK by various drugs
of abuse in vivo (Valjent et al., 2005). DARPP-32 regulates dephos-
phorylation of ERK by controlling the state of phosphorylation
and activity of the non-receptor striatal-enriched phosphatase
(STEP) and also acts upstream in the pathway (Valjent et al., 2005).
Here we summarize results implicating DARPP-32 in the actions
of drugs of abuse and focus on recent work, including studies in
which the role of individual phosphorylation sites of DARPP-32
has been studied (Svenningsson et al., 2003).
COCAINE AND AMPHETAMINE
Cocaine inhibits reuptake of dopamine and amphetamine trig-
gers the release of dopamine from nerves terminals. Acute expo-
sure to cocaine or amphetamine increased the phosphorylation
of DARPP-32 at Thr-34 and decreased the phosphorylation at
Thr-75 in striatal slices (Nishi et al., 2000b). In vivo, an acute injec-
tion of cocaine (20mg/kg) increased Thr-34 phosphorylation in
D1R-expressing neurons (Bateup et al., 2008). This treatment had
opposite effects on Thr-75 phosphorylation in D1R striato-nigral
neurons (decreased phosphorylation) and in D2R striato-pallidal
neurons (increased phosphorylation), with an overall decreased
phosphorylation (Bateup et al., 2008). In contrast, chronic expo-
sure to cocaine-induced an increase of phosphorylation at Thr-75
(Bibb et al., 2001). This effect was attributed to the up-regulation
of Cdk5, resulting from an over-expression of Δ-Fos B after a
chronic exposure (Bibb et al., 2001).
Repeated administration of psychostimulants in rodents is
accompanied by an increased locomotor response, termed loco-
motor or psychomotor sensitization (Vezina and Leyton, 2009).
Locomotor sensitization was increased when cocaine was repeat-
edly administered in the presence of a Cdk5 inhibitor (Bibb et al.,
2001), supporting a negative role of the phosphorylation of Thr-
75 and/or other targets. However, contrary to what might have
been predicted, Thr-34-Ala point mutation increased locomotor
sensitization to repeated administration of cocaine in knock-in
mutant mice, whereas Thr-75-Ala mutation point prevented sen-
sitization (Zachariou et al., 2006). An increased sensitization was
also observed in complete knockout mice in response to repeated
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cocaine (Hiroi et al., 1999). A strong and long-lasting sensitization
can be induced in rats or mice in response to a single injection of
cocaine or amphetamine, attesting to the powerful effects of these
drugs on neuronal plasticity (Vanderschuren et al., 1999; Valjent
et al., 2010). Using this protocol, sensitization to a single injection
of cocaine was markedly decreased in Thr-34-Ala mutant mice
(Valjent et al., 2005). These discrepancies may be related to dif-
ferent mechanisms underlying sensitization in response to single
and repeated drug injections and/or to minor differences in the
experimental protocols which are highly sensitive to conditioned
cues (Vezina and Leyton, 2009).
Conditioned place preference (CPP) to cocaine was diminished
in full knockout (Hiroi et al., 1999) and in Thr-34-Ala knock-
in DARPP-32 mutant mice (Zachariou et al., 2002). Locomotor
sensitization and CPP were also decreased in DARPP-32 Ser-97-
Ala mutant mice, in which DARPP-32 is mostly trapped in the
nucleus (Stipanovich et al., 2008). Acquisition of stable cocaine
self-administration required signiﬁcantly more time in Thr-34-
Ala mice, although both Thr-34-Ala and Ser-130-Ala DARPP-32
mutant mice self-administered more cocaine than their respec-
tive wild-type controls (Zhang et al., 2006). Thus it appears that
DARPP-32 is involved in the chronic effects of psychostimu-
lants, although its role is not simple. Its loss of function delays
or impairs the acquisition of cocaine conditioned behavior, but
may limit locomotor sensitization to repeated administration and
self-administration.
MORPHINE
Morphine and heroin are thought to exert their addictive effects at
several levels. They increase the ﬁring of DAneurons by decreasing
at the presynaptic level the inhibitory input to these neurons and
also act directly in the NAc (see Luscher and Malenka, 2011 for
a review). Acute locomotor effects of morphine were decreased
in Thr-34-Ala mutant mice, whereas locomotor sensitization to
repeated injections and CPP were unaltered (Borgkvist et al.,
2007). In contrast, sensitization to a single injection of morphine
was markedly decreased in Thr-34-Ala mutant mice (Valjent et al.,
2010), and in Ser-97-Ala mutant mice (Stipanovich et al., 2008).
Thus, modulation of the behavioral effects of psychostimulants
and morphine by DARPP-32 appear to be different depending on
whether the drug is administered once or repeatedly. Following
a single administration DARPP-32 seems to amplify the effects
of the drugs and to be necessary for long-term plasticity. In con-
trast, following repeated administration, it appears to moderate
the effects in a somewhat homeostatic fashion.
CAFFEINE
Caffeine is a commonly used minor psychostimulant,which exerts
its effects mostly through antagonism of A2 adenosine receptors
(A2AR), located in the striato-pallidal neurons of the indirect
pathway (Ledent et al., 1997). It is not considered as a drug of
abuse and has little or no addictive properties (Satel, 2006). A2AR
are coupled to Golf and stimulate cAMP production (Kull et al.,
2000; Corvol et al., 2001). DARPP-32 is necessary to mediate
the psychostimulant effects of caffeine (Lindskog et al., 2002).
This may be related to the increase in Thr-75 phosphorylation,
which results from an inhibition of PP2A (Lindskog et al., 2002)
and occurs selectively in striato-pallidal neurons (Bateup et al.,
2010). These results further support the precise functional bal-
ance between the striato-nigral and striato-pallidal neurons and
suggest that decreased signaling in one pathway (here PKA inhi-
bition through phospho-Thr-75-DARPP-32) has effects similar to
stimulation of signaling in the other pathway (e.g., stimulation of
PKA/phospho-Thr-34-DARPP-32 by D1R).
NICOTINE
Nicotine enhances dopamine release by the nigrostriatal and pref-
erentially mesolimbic dopaminergic systems, in vitro and in vivo
(Giorguieff Chesselet et al., 1979; Imperato et al., 1986). In striatal
slices nicotine at low concentration (1μM) decreased phospho-
rylation of DARPP-32 at Thr-34, whereas at high concentration
(100μM) it increased phosphorylation of Thr-34, as well as Ser-
102, Ser-137, and, with a delay, decreased Thr-75 phosphorylation
(Hamada et al., 2004, 2005). In vivo, however, nicotine increased
phosphorylation of both Thr-34 and Thr-75 (Zhu et al., 2005).
Interestingly DARPP-32 knockout mice had an increased respon-
siveness to nicotine including a higher oral intake of the drug, sug-
gesting that the “inhibitory” effect of Thr-75 plays a predominant
role (Zhu et al., 2005).
THE ROLE OF SEROTONIN AND NOREPINEPHRINE
Psychostimulants increase not only extracellular dopamine but
also serotonin (5OH-tryptamine, 5HT) and norepinephrine. In
the striatum, stimulation of 5HT-4 and 5HT-6 receptors increases
phosphorylation of DARPP-32 on Thr-34 and decreases its phos-
phorylation on Thr-75, while stimulation of 5HT-2 receptors
enhances Ser-130 (Ser-137 in the rat) phosphorylation (Sven-
ningsson et al., 2002a). Similar effects were observed after acute
or chronic administration of the selective serotonin reuptake
inhibitor ﬂuoxetine (Svenningsson et al., 2002b). The regula-
tion of DARPP-32 by 5HT may be functionally relevant since
the behavioral effects of various agents that raise 5HT levels
in vivo including 5-OH-tryptophan, p-chloroamphetamine, and
ﬂuoxetine were decreased in DARPP-32 knockout mice (Sven-
ningsson et al., 2002a,b). The phosphorylation of DARPP-32 on
the sites mentioned above was also regulated following admin-
istration of psychotomimetic compounds acting through diverse
mechanisms, including amphetamine, lysergic acid diethylamide
(LSD, predominantly a 5HT2A agonist), and phencyclidine (an
NMDA antagonist; Svenningsson et al., 2003). The behavioral
effects of these drugs were altered in knock-in mice with point
mutations of either Thr-34 or Ser-130 (Svenningsson et al., 2003).
Interestingly, DARPP-32 Thr-34 phosphorylation is also regu-
lated by adrenoceptors in striatal slices with a stimulatory effect
of β1-adrenoceptors in both striato-nigral and striato-pallidal
neurons (Hara et al., 2010). These results support the implica-
tion of DARPP-32 far beyond the DA receptors that may con-
tribute to the role of this protein in the action of drugs of
abuse.
ROLE OF DARPP-32 IN OTHER BRAIN REGIONS
The initial study of DARPP-32 immunoreactivity in the brain of
adult rats showed its abundance in brain regions that receive a
strong dopamine input (striatum, olfactory tubercle, bed nucleus
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of the stria terminalis, massa intercalata, and amygdaloid nuclei;
Ouimet et al., 1984). Weakly labeled neuronal cell bodies and den-
drites were found in the Purkinje neurons of the cerebellum, as
well as in certain glial cells, especially in the median eminence, in
the arcuate nucleus, and medial habenula (Ouimet et al., 1984).
In the rat cerebral cortex DARPP-32 is expressed throughout the
neocortex, primarily in layer VI corticothalamic neurons (Ouimet
et al., 1984; Ouimet, 1991). DARPP-32 is also found in the monkey
cortex with a widespread distribution in the fetus, which becomes
more restricted in the adult (Berger et al., 1990). DA signaling
in the prefrontal cortex (PFC), which receives dense DA projec-
tions from the VTA, has been established to play a critical role
in animals’ performance in both working memory and selective
attention tasks (Goldman-Rakic et al., 2000). D1R and D2R are
expressed in the rat PFC, in layers VI and V respectively (Gaspar
et al., 1995). The positive effects of a D1R agonist on a recognition
and temporal order memory task were associated with increased
phosphorylation of DARPP-32 on Thr-34 in the PFC but not in
the hippocampus, whereas a D1R antagonist decreased the perfor-
mance andThr-34 phosphorylation (Hotte et al., 2006).Moreover,
in mice the levels of expression in the PFC of several DA signal-
ing related genes, including DARPP-32, were positively correlated
with animals’ general cognitive performance (Kolata et al., 2010).
DARPP-32 also appears to play a role in progesterone-
dependent sexual behavior. Vaginal–cervical stimulation was
reported to increase the number of cells exhibiting pThr-34-
DARPP-32 immunoreactivity in the medial preoptic nucleus,
the caudal ventromedial hypothalamic nucleus, the posterodor-
sal medial amygdala, and the bed nucleus of the stria terminalis,
although the total amount of protein was not veriﬁed (Meredith
et al., 1998). Progesterone enhanced DARPP-32 Thr-34 phospho-
rylation in the hypothalamus of female rats, independently from
D1R (Mani et al., 2000). The role of DARPP-32 in the behavioral
effects of progesterone was indicated by the decreased lordosis
after injection of DARPP-32 antisense nucleotides in the third
ventricle or in DARPP-32 knockout mice (Mani et al., 2000). In
addition to its role in brain, DARPP-32 may be involved in sex-
ual hormone action at the peripheral level since it is expressed in
ovarian endocrine cells (Mayerhofer et al., 1999). Although repro-
ductive performance is not altered in adult DARPP-32 knockout
mice, progressive alterations and derangements of growth and
development of ovarian follicles are observed, suggesting prema-
ture ovarian aging (Mayerhofer et al., 2004). A recent study has
shown that DARPP-32 as well as other DA-related gene prod-
ucts,were upregulated in lateral hypothalamic orexinergic neurons
by sodium deﬁciency (Liedtke et al., 2011). These observations
suggest an evolutionary connection between the hypothalamic
mechanisms of salt appetite and hedonic liking of salt taste, and
possibly also mating behavior, with other D1R-regulated reward
systems.
DARPP-32 IN HUMAN PHYSIOLOGY AND PATHOLOGY
DARPP-32 IN HUMAN NEUROPSYCHIATRIC DISEASES AND
PSYCHOLOGICAL TRAITS
DARPP-32 mRNA is expressed in the human brain with a dis-
tribution similar to that found in monkey and rodents, with
high levels in the caudate, putamen, NAc, choroid plexus, and
low levels in the cerebral cortex, CA1 and CA3 regions of the
hippocampus, amygdala, and Purkinje cells (Brené et al., 1994).
In the PFC DARPP-32 mRNA levels increase with age (Colan-
tuoni et al., 2008). Studies of DARPP-32 alterations in humans
include measurements in post-mortem tissues using biochemical
and immunohistochemical methods, as well as genetic analyses.
Expression of DARPP-32 is not changed by the massive alteration
in DA innervation in patients with Parkinson’s disease or pro-
gressive supranuclear palsy (Girault et al., 1989b; Raisman-Vozari
et al., 1990). One of the difﬁculties of studies of human brain
samples is the variability of the levels of DARPP-32, as those of
several other proteins,with the post-mortem delay, requiring care-
ful matching of delays and large sample size (Girault et al., 1989b).
Studies in rodents conﬁrmed the independence of DARPP-32
expression levels from striatal DA innervation during develop-
ment and following lesions of nigrostriatal neurons (Ehrlich et al.,
1990; Raisman-Vozari et al., 1990; Brown et al., 2005). In con-
trast, a decreased DARPP-32 immunoblot signal was reported in
the dorsolateral PFC of schizophrenic patients in comparison to
matched controls (Albert et al., 2002). A decreased number of
DARPP-32-positive neurons was also observed by immunohisto-
chemistry in the superior temporal gyrus of schizophrenic patients
compared to age and sex-matched control subjects (Kunii et al.,
2011). Another study reported a decreased level in the dorsal PFC
of schizophrenic and bipolar patients (Ishikawa et al., 2007). In
contrast to these convergent results on protein levels, results con-
cerning DARPP-32 mRNA levels were variable depending on the
studies: unchanged in the dorsal prefrontal and anterior cingulate
cortex of elderly schizophrenic patients (Baracskay et al., 2006), or
slightly increased in the PFC of schizophrenic and bipolar patients
(Zhan et al., 2010), or slightly decreased in schizophrenic patients
who died by suicide (Feldcamp et al., 2008). A decreased number
of leukocytes expressing DARPP-32 was also reported in schizo-
phrenic and bipolar patients (Torres et al., 2009). Post-mortem
studies in humans have intrinsic limitations and the signiﬁcance
of these intriguing ﬁndings is unclear. The existence of DARPP-32
alterations in both schizophrenia and bipolar disorder may not
be surprising since the limits between these two entities appear
less strict than initially thought, as recent studies identify com-
mon susceptibility genes (Bondy, 2011).However, both conditions
are unlikely to be homogenous, and it is possible that decreased
DARPP-32 levels in the cortex aremeaningful only in subgroups of
patients yet to be identiﬁed.Whether these changes are a cause or a
consequence of the disease process also remains to be determined.
It is unlikely that the changes result from chronic antipsychotic
treatment since such treatment did not alter DARPP-32 levels
in rodents (Grebb et al., 1990; Souza et al., 2008). In contrast,
chronic treatment of rats with lithium or other antidepressants
increased DARPP-32 levels in the frontal cortex (Guitart and
Nestler, 1992).
PPP1R1B, the gene encoding DARPP-32, is located at 17q21,
in or near a region possibly implicated in risk for schizophrenia
by a meta-analysis of whole genome linkage (Lewis et al., 2003).
A polymorphism in the PPP1R1B gene has been identiﬁed with-
out association with schizophrenia in Chinese Han (Li et al., 2006;
Hu et al., 2007) and Japanese (Yoshimi et al., 2008) populations.
Another study in the USA identiﬁed a frequent PPP1R1B
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haplotype predicting mRNA expression of DARPP-32 isoforms
in post-mortem human brain (Meyer-Lindenberg et al., 2007).
This haplotype was associated with enhanced performance in sev-
eral cognitive tests that depend on frontostriatal function and
increased frontostriatal connectivity in multimodal brain imag-
ing. It was also associated with the risk for schizophrenia in a
family based association analysis (Meyer-Lindenberg et al., 2007).
Possible links between PPP1R1B polymorphisms and personality
traits have also been studied. A single nucleotide polymorphism
(C→T in intron 5) was associated to self-reports of anger in
a German Caucasian population (Reuter et al., 2009). Another
study conducted in healthy Chinese Han subjects found a corre-
lation between several SNPs in PPP1RB and traits of personality
such as harm avoidance or novelty seeking (Li et al., 2011). A par-
ticular haplotype (present in 32% of the subjects) in PPP1RB was
linked to smoking quantity in a European-American cohort but
not in an Afro-American one (Beuten et al., 2007). All these asso-
ciation studies are intriguing but at best correlative. Their validity
will have to be conﬁrmed by the replication of the associations in
similar and different genetic backgrounds.
DARPP-32 SHORT ISOFORM AND CANCER
Both DARPP-32 and a shorter isoform lacking the 36 N-terminal
residues and termed truncated DARPP-32 (t-DARPP) are over-
expressed in gastric cancer (El-Rifai et al., 2002). The translation of
t-DARPP-32 is initiated at an internal site,Met-37, from an mRNA
encompassing an alternative ﬁrst exon located within intron 1 of
DARPP-32 (El-Rifai et al., 2002; Figure 4). This transcript has
also been detected in human brain (El-Rifai et al., 2002; Meyer-
Lindenberg et al., 2007). t-DARPP-32 lacks the N-terminal region
involved in PP1 inhibition. The physiological role of t-DARPP-32,
if any, is not known and Met-37 is not conserved in all species (e.g.,
it is absent in rat). In contrast t-DARPP may play an important
role in human cancer cells. In gastric adenocarcinoma, t-DARPP
promotes cell survival through an increase in Bcl2 levels medi-
ated by a pathway involving activation of Akt, CREB, and ATF1
(Belkhiri et al., 2008). t-DARPP is over-expressed in breast cancer
cells resistant to herceptin™, a therapeutic monoclonal antibody
that blocks erbB2 (Gu et al., 2009; Hamel et al., 2009). This effect
involves phosphorylation of Thr-75 and activation of Akt, and
is antagonized by full length DARPP-32 (Gu et al., 2009; Hamel
et al., 2009). Interestingly, the effects of t-DARPP-32 are mediated
inpart by activationof β-catenin-dependent transcription (Vanga-
mudi et al., 2011). In both breast and upper gastrointestinal tract
cancer cells, t-DARPP-32 appears to activate Akt upstream from
phosphatidylinositol-3-kinase (Vangamudi et al., 2010, 2011).
Another link between DARPP-32 and transformed phenotype
has been identiﬁed in breast cancer. DARPP-32 binds to the jux-
tamembrane region of unstimulated discoidin domain receptor-1
(DDR1), a receptor tyrosine kinase activated by collagen (Hansen
et al., 2006). Co-expression of the two proteins inhibited cell
migration and ﬁlopodia formation through phosphorylation of
DARPP-32 Thr-34 in response to Wnt-5a activation of cAMP
production and PKA (Hansen et al., 2006, 2009). These results
are interesting since they identify t-DARPP as a potential thera-
peutic target in cancer. They also suggest the existence of novel
signaling function of this protein that remain to be elucidated at
the molecular level but which might also be relevant in neurons.
CONCLUSION
DARPP-32 is one of several PKA-regulated inhibitors of PP1 and
has additional functions which endow it with a large number of
possible regulatory roles. DARPP-32 is highly expressed in spe-
ciﬁc cells especially in neurons, among which the striatal MSNs
have the highest DARPP-32 concentration. Its phosphorylation
has been thoroughly investigated and DARPP-32 is the hub of a
rich network of regulations. It controls an amazingly wide vari-
ety of properties of MSNs from ion channel permeability and
synaptic plasticity, to nuclear chromatin response. The combina-
tion of experimental and modeling studies suggests that in MSNs
DARPP-32 is a robust integrator of signaling whose main role may
be to increase the reliability in decoding the information medi-
ated by glutamate and DA, as well as other inputs. As such it
may not be essential for the basal functioning of the basal ganglia
and cortex, but it may perhaps be expected to increase evolution-
ary ﬁtness by improving performance in challenging conditions.
FIGURE 4 | Exon organization of human DARPP-32 and its truncated
isoform. Schematic representation of the DARPP-32 (PPP1R1B) gene
(green, middle) with introns (green lines with length below) and exons
(green boxes with number in white and length above). DARPP-32 protein
and the short isoform, t-DARPP-32 are indicated in magenta. The length
of exons and introns is indicated in base pairs (bp) and the borders of
coding exons in amino acid residues in protein sequences. The position
of major phosphorylation sites is indicated on the proteins (S, serine, T,
threonine). The scheme is based on El-Rifai et al. (2002) and NCBI
sequences.
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Accordingly the use of a variety of sophisticated mouse models
has shown that DARPP-32 mutations do not appear to have severe
consequences on spontaneous behavior in laboratory conditions.
In contrast these mutations alter the effects of a large number
of therapeutic and abused drugs, which represent pharmacolog-
ical challenges. Similarly, so far no mutation of DARPP-32 has
been clearly associated with a human pathology. However, conver-
gent evidence in mice and human suggests that DARPP-32 may be
associatedwith general cognitive performance (Meyer-Lindenberg
et al., 2007; Kolata et al., 2010). Thus, the intricate regulations pro-
vided by a regulatory molecule such as DARPP-32 may have been
selected during vertebrate evolution to optimize brain functions
without being absolutely necessary for any of them. It is interest-
ing that the PPP1R1/DARPP-32 family of PP1 inhibitors seems to
have originated in early Gnathostomes. This latter type of verte-
brates arguably display a more complex behavioral repertoire than
jawless animals (Agnathans) and PP1 inhibitors may have con-
tributed to this evolution. In humans, DARPP-32 polymorphisms
have been linked to personality traits and could predispose to
psychopathological states. Thus, DARPP-32 is, in principle, an
interesting target for pharmacological interventions, with possi-
bilities for enhancing or preventing modulatory functions with-
out altering vital mechanisms. Yet, the molecular properties of
DARPP-32, mostly an unstructured protein, do not provide sim-
ple binding sites for small molecules making the design of efﬁcient
drugs a challenging task. Alteration of its level of expression
through gene targeting may be a better way to exert therapeutic
effects not only in neuropsychiatry, but also in cancer.
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